In this Issue:
Lanreotide an option in neuroendocrine tumours?
Erlotinib in metastatic PAC progressing after gemcitabine
Gemcitabine + oxaliplatin ± cetuximab in biliary cancer
Gefitinib as second-line in oesophageal cancer
Physical activity lowers mortality in cancer survivors
Chemotherapy-induced cognitive alterations
Communication skills training benefits oncologists
Select therapy according to tumour molecular profiling?
Amoxapine: potential in irinotecan-induced diarrhoea?
Everolimus: not recommended for HCC
Please login below to download this issue (PDF)